Xu, Jingshu http://orcid.org/0000-0002-0130-348X
Church, Stephanie J.
Patassini, Stefano
Begley, Paul
Kellett, Katherine A. B.
Vardy, Emma R. L. C.
Unwin, Richard D.
Hooper, Nigel M.
Cooper, Garth J. S.
Funding for this research was provided by:
The University of Manchester, the Central Manchester University Hospitals NHS Foundation Trust, the Northwest Regional Development Agency
Medical Research Council (MR/L010445/1)
Biotechnology and Biological Sciences Research Council (BB/I018654/1)
Endocore Research Associates (60187, 3601607)
Maurice and Phyllis Paykel Trust; Lottery Health
Health Research Council of New Zealand
Ministry for Business, Innovation, and Employment (UOAX9902, PMIX0201, UOAX0705, UOAX0815)
Article History
Received: 11 December 2017
Accepted: 26 February 2018
First Online: 7 March 2018
Compliance with ethical standards
:
: GJSC is named as inventor on patents disclosing Cu-selective chelators for the treatment of the diabetic complications and related diseases: these patents have been licensed and he has no financial interest in this work and declares no other duality of interest. All the other authors declare that they have no duality of interest with respect to this manuscript.